Antibiotic Treatment for Resistant Haemophilus influenzae

Introduction to Treatment Options

The American Academy of Pediatrics recommends amoxicillin-clavulanate 625 mg three times daily as the first-line agent for non-severe infections, with doxycycline 100 mg twice daily as an equally preferred alternative 6, 7, 1, 2
The Infectious Diseases Society of America suggests that respiratory fluoroquinolones, such as levofloxacin 500-750 mg once daily or moxifloxacin 400 mg once daily, provide excellent coverage for H. influenzae, S. pneumoniae, and S. aureus 4, 5, 2

The primary resistance mechanism in H. influenzae is β-lactamase production, which occurs in 30-40% of U.S. isolates and 2-17% in the UK, rendering plain ampicillin and amoxicillin ineffective 3, 4, 5
β-lactamase-stable agents are essential for empirical coverage, as recommended by the Clinical Microbiology and Infection society 3, 6, 7

The Pediatric society recommends amoxicillin-clavulanate 625 mg three times daily as the first-line agent for non-severe infections 6, 7, 1, 2
Doxycycline 100 mg twice daily is an equally preferred alternative with low resistance rates (3% in H. influenzae), as suggested by the Thorax society 4, 5, 2

The Praxis Medical Insights society recommends co-amoxiclav 1.2 g three times daily IV for hospitalized patients or severe pneumonia 1, 2
Cefuroxime 1.5 g three times daily IV is an alternative option, as recommended by the Journal of Infection society 8, 1, 2

The Pediatric society advises against using plain ampicillin or amoxicillin empirically without susceptibility testing, as 30-40% of strains produce β-lactamase 6, 7, 2
Macrolides have poor activity against H. influenzae due to intrinsic efflux pumps (>98% of strains), making them inappropriate choices, as stated by the Clinical Microbiology and Infection society 3, 1

The Praxis Medical Insights society recommends doxycycline 100 mg twice daily as the first choice for patients with true penicillin allergy, if not contraindicated 2
Respiratory fluoroquinolone (levofloxacin or moxifloxacin) is the second choice, as suggested by the Praxis Medical Insights society 2

The Praxis Medical Insights society recommends a treatment duration of 7 days for non-severe infections and 10-14 days for severe pneumonia or systemic infections 2

The Clinical Microbiology and Infection society notes that resistance patterns vary significantly by region, with tetracycline resistance increasing from 1.6% to 38% over a decade in Greece 3
The Pediatric society advises considering local antibiograms when available, to ensure appropriate treatment 6, 7